\
&
Contact us
\
&
Contact us
The ICT-Leadership in Enabling and Industrial Technologies (LEIT) Work Programme under H2020 provides a balanced response to the main challenges faced by Europe in the field: firstly, the need to maintain a strong expertise in key technology value chains; secondly, the necessity to move quicker from research excellence to the market.
It combines a strong support to industrial roadmaps with new mechanisms to encourage disruptive innovation. The former will reinforce medium to long term commitment to industrial strategies and provide continuity and stability. The latter will offer flexibility and openness and will help develop dynamic eco-systems in which innovators can operate. Both strands will require the involvement of new actors, on one hand to exploit and leverage new technologies and on the other to initiate and drive change.
Six main activity lines have been identified in the ICT-LEIT part of the Work Programme:
In addition, the Work Programme features several cross-cutting topics addressing cyber-security, Internet of Things and research on a Human-centric Digital Age. All activities are complemented with support to innovation and take-up, international cooperation and a dedicated action for SMEs to propose bottom-up innovative ideas, using the SME instrument.
nico.deblauwe@vlaio.be
+32 2 432 43 00
Find the contact info on the site of WEWIS
The National Contact Points (NCPs) provide support, guidance, and practical information to potential applicants, helping them navigate funding opportunities and application processes.
The Programme Committee (PC) members represent their country in decision-making about the work programmes, evaluate implementation, and provide strategic input on priorities and calls.
Infosheets contain edited content on aspects related to this programme. They are reviewed at least yearly.
Related links are easy pointers towards external information. We curate the list, but are not liable for the destinations.
Documents contain additional information related to this programme, and are similar to related links.
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
